Supplements
curcumin prevents cancer
In plain terms: Does turmeric fight or prevent cancer?
Insufficient(Laboratory findings not confirmed in people) Supplements 🔬 Includes disconfirming
Part of: 🧪 turmeric & curcumin
RefutedContestedStrong support
consensus score 0.37
⚖️ Thin evidence — read the needle loosely. The score shows which way the studies lean, but there are too few independent, high-quality ones to place it firmly. Expect this to move as better evidence arrives.
Not shown in people — this is the biggest turmeric myth. Curcumin looks dramatic against cancer cells in a dish and in mice, but it is so poorly absorbed that decades of human trials have found no cancer prevention or treatment. Lab story, no human evidence.
🧭 Read this score with how it was built in mindLab and animal results no longer outvote a human study that found nothing
Nineteen cell and animal studies support it; the one human randomised trial that tested it, in people with precancerous stomach changes, found no effect. A meta-analysis of curcumin for radiation injury in cancer patients was also set aside, because treating radiation damage is not preventing cancer.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
19 support 1 contradict 0 tested null 6 mixed · 26 sources, 20 independent groups
What the evidence shows
The biggest turmeric myth, and the weakest evidence. Curcumin kills cancer cells impressively in a petri dish and slows tumors in mice — but that has not translated to humans: because it's so poorly absorbed, clinical trials over decades have not shown curcumin prevents or treats any cancer. Strong lab story, no established human benefit.
The evidence (37)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Booravilli J, Sirisolla JD 2026 · Nanomedicine (London, England) | in-vitro | supports | low | Curcumin nanoemulgel formulation tested for cytotoxicity/apoptosis against skin cancer cell lines (A431); IC50 in the ~123 micromolar range. |
| Kobylka P, Murias M, Bakun P, Goslinski T, Kucinska M 2026 · Toxicology in vitro : an international journal published in association with BIBRA | in-vitro | supports | low | Curcumin derivatives tested for cytotoxicity in human muscle-invasive bladder cancer cell line (HT-1376) under normoxia/hypoxia vs normal bladder cells. |
| Attri K, Sharda D, Tanwar I, Gautam P, Choudhury D 2026 · Scientific reports | in-vitro | supports | low | Curcumin-stabilized silver nanoparticles showed antimicrobial (anti-H. pylori) and cytotoxic activity against AGS gastric adenocarcinoma cells in vitro. |
| Hu L, Yin Z, Tan S, Deng Y, Qu X, Hu T, Wang Q 2026 · Materials today. Bio | animal | supports | moderate | Nanoceria-curcumin platform enhanced radiotherapy efficacy in triple-negative breast cancer in vitro and in vivo (mouse xenograft); a radiosensitizer adjunct-to-treatment study. |
| Bisht M, Gomes MC, Bordon Sosa FH, Mano JF, Pandey S, Ventura SPM, Coutinho JAP 2026 · Scientific reports | in-vitro | mixed | low | Ionic-liquid solubilization of curcumin increased aqueous solubility ~8000-fold and reduced viability of MDA-MB-231 breast cancer cells in vitro without harming normal fibroblasts. |
| Anghelache M, Voicu G, Safciuc F, Turtoi M, Deleanu M, Movileanu C, Ficai D, Ficai A, Calin M 2026 · The Journal of pharmacy and pharmacology | animal | supports | low | Nanoparticle-targeted curcumin delivery tested in LPS-treated mice (biodistribution/safety) and MCF-7/A549 cancer cell lines (apoptosis assays). |
| Zhou C, Hu C, Wang B, Fan S, Jin W 2026 · Cancer biotherapy & radiopharmaceuticals | in-vitro | supports | low | Curcumin suppressed proliferation/migration/invasion of Hep3B and Huh-7 hepatocellular carcinoma cell lines via miR-21-5p/SOX6 axis. |
| Alam S, Lee J, Sahebkar A 2024 · Curr Pharm Des | observational | mixed | low | Review of cancer-prevention trials: some signals exist but poor bioavailability limits translation; no established preventive efficacy. |
| Panknin TM, Howe CL, Hauer M, Bucchireddigari B, Rossi AM, Funk JL 2023 · Int J Mol Sci | observational | mixed | low | Scoping review of clinical trials: curcumin studied across many conditions, but cancer-prevention/treatment evidence remains preliminary. |
| Arjona-Ruiz C, Valdez-Morales EE, Guerrero-Alba R 2026 · Anticancer Agents Med Chem | in-vitro | mixed | low | Narrative review, not evidence: 'This review compiles in vitro, in vivo, and clinical evidence on the anticancer activity of polyphenols in CRC.' Curcumin trials: 'some studies demonstrating reductions in ACF ... while others have demonstrated no significant clinical benefit.' Review — zero weight. |
| Li J, Pandit S, Manupati K, Wang A, Zaman SU, Cen Y 2026 · Biochimica et biophysica acta. Molecular basis of disease | animal | supports | moderate | Curcumin inhibited FOSL1/JUN signaling in head-and-neck squamous cell carcinoma cell lines and suppressed tumor growth in a xenograft mouse model, with efficacy compared to a targeted inhibitor. |
| Hu N, Yan N, Zhao T, Hu L 2026 · Pakistan journal of pharmaceutical sciences | animal | supports | moderate | Mouse liver-cancer model; curcumin dose-dependently inhibited STAT3 signaling and improved liver injury/biochemical markers. Mechanistic/cytotoxicity-adjacent effect, not human cancer prevention. |
| Almutairi JA, El-Masry TA, El-Bouseary MM, El Zahaby EI, Wahsh E, Mohamed NA, Hashem HM, Abdel-Kareem NM, Alenazi N, El-Nagar MMF 2026 · BMC biotechnology | in-vitro | supports | low | Curcumin nanocrystal/spanlastic formulations showed antimicrobial, antioxidant, and cytotoxic (MCF-7) activity in vitro. |
| Rekaibi CI, Billa N 2026 · J Biomater Sci Polym Ed | in-vitro | mixed | low | Narrative review, not evidence: 'In composing this review, relevant literature identified in major databases ... was sought.' Concludes 'direct evidence supporting curcumin-specific mucopenetrative nano-formulations in clinically relevant cancer models remains very limited.' Therapy-delivery topic, not prevention. Review — zero weight. |
| d10-3390-org7030030 2026 · Organics | in-vitro | mixed | low | Narrative review of curcumin analogs designed against pancreatic cancer (PDAC), synthesizing preclinical anti-inflammatory/pro-apoptotic/antimetastatic activity of curcumin-derived compounds, not curcumin itself in humans. |
| Gupta SC, Patchva S, Aggarwal BB 2013 · AAPS J | observational | mixed | low | Clinical-trials review: despite strong preclinical anticancer activity, curcumin's human efficacy is limited by poor bioavailability; benefit unproven. |
| Oransa WW, Zahran RF, El Sadda RR, Toson EA 2026 · Scientific reports | in-vitro | mixed | low | Curcumin-loaded ZIF-8 nanocomposites cytotoxic to HepG-2 and MDA-MB-231 cell lines in vitro, with selectivity over normal MRC-5 cells. |
| Zhan L, Qia M, Cha Y, Gao X 2026 · BMC cancer | meta-analysis | tested-null | high | GRADE-based systematic review/meta-analysis of curcumin for radiation-induced injury (RII) in cancer patients undergoing radiotherapy; curcumin reduced severe RII incidence and severity scores but showed no significant effect on overall RII |
| Liu B, Xiao L, Shi J, Zhang J, Chen M 2026 · Translational cancer research | in-vitro | supports | low | Curcumin reduced migration/EMT markers in HCT116 and SW620 colorectal cancer cell lines via IKKbeta/NF-kB/Snail pathway. |
| Asakere S, Zahedi AM, Heydari S, Matloubi Z, Nosratabadi R, Khalilabadi RM, Langroudi L 2026 · Scientific reports | in-vitro | supports | moderate | BSA-curcumin nanoparticles selectively killed MCF-7 breast cancer cells and modulated immune co-culture cytokines in vitro; no animal or human data. |
| Liu L, Jiang J, Wu Z, Wu X, Peng J, Xu N, Lin X, Sun R, Kang Y, Ke C, Zhao C, Huang Q, Gao F, Zeng Y, Yuan Z 2026 · Drug delivery and translational research | animal | supports | moderate | Curcumin/TRAIL co-delivered via engineered extracellular vesicles reduced tumor growth in a renal-cell-carcinoma xenograft mouse model; synergy with TRAIL, not curcumin alone. |
| LeBlanc K, Brewer E, Aggarwal S 2026 · Nutrients | mechanism | mixed | low | Narrative review of inflammation-cancer biology and curcumin's NF-kB/STAT3 mechanisms; says 'its clinical application is limited by poor bioavailability'. No cancer-incidence data. Review — zero weight. |
| Rabba'a MM, Abu-Zurayk RA, Bustanji YK, Abu-Irmaileh B, Mallouh SA, Khalaf A 2026 · Toxicology reports | in-vitro | mixed | low | Curcumin-chitosan-carbon-nanotube formulations cytotoxic to A549, HCT116, and PANC1 cancer cell lines in vitro. |
| Ahmad A, Bagwe D, Khan S, Dhone C, Padhare S, Alghamdi AA, Khan SA 2026 · Pharmaceuticals (Basel, Switzerland) | in-vitro | supports | low | Albumin nanocarrier-delivered curcumin showed cytotoxicity against Colo-205 colon cancer cell line in vitro; authors note findings limited to in vitro evaluation. |
| Tamilselvan P, Aishwarya S, Praveen Kumar PK 2026 · Phytomedicine | mechanism | mixed | low | Narrative review, not evidence: 'This review aims to comprehensively summarize the chemical, molecular, pharmacological, and computational insights into curcumin's anticancer mechanisms'; concludes 'strong mechanistic and preclinical activity ... but its translational relevance remains uneven'. Review — zero weight. |
| Pinto L, Silva JPN, Monteiro L, Silva PMA 2026 · Int J Mol Sci | in-vitro | mixed | low | Narrative review, not evidence: 'This review critically evaluates the current preclinical and translational evidence supporting curcumin and its derivatives as monotherapeutic agents in HNC'; advantages 'have not yet translated into robust clinical evidence.' Review — zero weight. |
| Sukumaran N, Senbagavadivoo SC, Raman A, Tamizhmani P, Packiaraj G, Velusamy T 2026 · In silico pharmacology | in-vitro | supports | low | Network pharmacology/molecular docking plus in-vitro radiosensitivity testing in MDA-MB-231 breast cancer cells; curcumin/resveratrol as radio-modulators. |
| Liu N, Cui YT, Zheng Y, Fang SM, Liao LX, Luo TT, Zhong ZH, Hu XY, Zhou MH, Tu YY 2026 · American journal of cancer research | in-vitro | supports | low | Curcumin induced ferroptosis/apoptosis in SK-OV-3 and A2780 ovarian cancer cell lines via Nrf2/GPX4 axis. |
| Mousavi S, Azad M, Karami Chermahini N, Momeni A 2026 · Asian Pacific journal of cancer prevention : APJCP | in-vitro | supports | low | Curcumin altered DNA methylation of DNMT1/CDH1/SMG1/WT1 genes in MIAPaCa2 pancreatic cancer cell line. |
| Qi X, Zhang H, Wang S, Qiao L, Ma L, Zhang K, Wang Y 2026 · Discover oncology | in-vitro | supports | low | Network pharmacology and molecular docking/dynamics simulations identifying curcumin-binding targets (AURKA, BRAF, CHEK1) in triple-negative breast cancer; purely computational. |
| Gonzalez-Pons M, Dominguez RL, Montalvan-Sanchez EE, Foster NR, Strand CA, Hernandez-Marrero J, Norwood DA, McMurray RP, Rivera Roman KL, Centeno-Girona H, Rodriguez-Murillo A, Ghandour F, Al Diffalha S, Samadder NJ, Umar A, Richmond E, Rodriguez LM, Limburg PJ, Morgan DR, Cruz-Correa M 2026 · Cancer prevention research (Philadelphia, Pa.) | RCT | contradicts | high | Phase IIa double-blind RCT of bioavailable curcumin (Meriva) in humans with gastric premalignant conditions; primary endpoint (gastric IL-1beta reduction) was met but secondary/histology/DNA-damage chemoprevention endpoints were unchanged b |
| Lu X, Song S 2026 · Current molecular medicine | mechanism | mixed | low | Narrative review of curcumin/resveratrol mechanisms in head-and-neck cancer progression and pain; notes 'clinical translation remains limited due to poor bioavailability' with only 'initial' small trials on mucositis. |
| d10-3390-ijms27146177 2026 · International Journal of Molecular Sciences | in-vitro | mixed | moderate | Systematic review of 101 network-pharmacology studies (with experimental validation) of plant-derived anticancer compounds including curcumin across lung/breast/colorectal/prostate cancer; explicitly identifies a 'persistent validation gap' |
| Ludwig N, Feldmann C, Spoerl S, Yerneni SS 2026 · Cancers | animal | supports | low | Extracellular-vesicle-delivered curcumin suppressed tumor progression in a murine (4-NQO) model of oral squamous cell carcinoma; reduced tumor number/burden in mice. |
| Prajapati KS, Kulkarni S, Choudhari S, Thareja S, Kumar S 2026 · Mini Rev Med Chem | in-vitro | mixed | low | Narrative review, not evidence: 'The present review focuses on recent updates on structural modifications of dietary phytochemicals that resulted in better antibreast cancer activity'; notes 'Poor water solubility and bioavailability contribute to the failure of these drugs in clinical trials.' Review — zero weight. |
| Hsu CH, Cheng AL 2007 · Adv Exp Med Biol | observational | mixed | low | Narrative review chapter, no new data: 'In phase I clinical studies, curcumin with doses up to 3600-8000 mg daily for 4 months did not result in discernible toxicities', bioavailability low; on efficacy across diseases including cancers 'the data to date are all preliminary and not conclusive.' Re-describes phase I trials - zero weight. |
| Zhang L, Duan X, Liu M, Li X 2026 · Frontiers in pharmacology | animal | supports | moderate | Systematic review and meta-analysis of animal (rodent xenograft) studies: curcumin reduced tumor weight/volume and increased apoptosis markers in breast cancer models; authors explicitly call for clinical trials. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.